Literature DB >> 11222829

Colchicine induced rhabdomyolysis.

I Chattopadhyay1, H G Shetty, P A Routledge, J Jeffery.   

Abstract

A case of colchicine induced rhabdomyolysis is reported. A 73 year old man with ischaemic heart disease, atrial fibrillation, chronic congestive cardiac failure, and chronic gout presented with diffuse muscle pain. He had been taking an increased dose of colchicine (1.5 mg daily) for an exacerbation of gout for six weeks before the presentation. Investigations confirmed the diagnosis of rhabdomyolysis and discontinuation of colchicine resulted in resolution of clinical and biochemical features of rhabdomyolysis. Although neuromuscular adverse effects of colchicine are well recognised, rhabdomyolysis is rare and this is only the fourth reported case of colchicine induced rhabdomyolysis in the literature.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11222829      PMCID: PMC1741937          DOI: 10.1136/pmj.77.905.191

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN: 0032-5473            Impact factor:   2.401


  7 in total

Review 1.  Management of gout in older adults: barriers to optimal control.

Authors:  Karl T Hoskison; Robert L Wortmann
Journal:  Drugs Aging       Date:  2007       Impact factor: 3.923

2.  Latest evidence on gout management: what the clinician needs to know.

Authors:  Christopher M Burns; Robert L Wortmann
Journal:  Ther Adv Chronic Dis       Date:  2012-11       Impact factor: 5.091

Review 3.  Colchicine-clarithromycin-induced rhabdomyolysis in Familial Mediterranean Fever patients under treatment for Helicobacter pylori.

Authors:  Oren Cohen; Garrett Locketz; Alon Y Hershko; Alexander Gorshtein; Yair Levy
Journal:  Rheumatol Int       Date:  2015-07-26       Impact factor: 2.631

4.  Colchicine-induced rhabdomyolysis.

Authors:  Arie Altman; Martine Szyper-Kravitz; Yehuda Shoenfeld
Journal:  Clin Rheumatol       Date:  2007-07-10       Impact factor: 2.980

5.  Hypouricemic and arthritis relapse-reducing effects of compound tufuling oral-liquid in intercritical and chronic gout: A double-blind, placebo-controlled, multicenter randomized trial.

Authors:  Zhijun Xie; Huaxiang Wu; Xiaoqing Jing; Xiuyang Li; Yasong Li; Yongmei Han; Xiangfu Gao; Xiaopo Tang; Jing Sun; Yongshen Fan; Chengping Wen
Journal:  Medicine (Baltimore)       Date:  2017-03       Impact factor: 1.889

6.  Clinical outcomes after colchicine overdose: A case report.

Authors:  Mingjie Fu; Jie Zhao; Zhitao Li; He Zhao; Anwei Lu
Journal:  Medicine (Baltimore)       Date:  2019-07       Impact factor: 1.817

7.  Adverse events during oral colchicine use: a systematic review and meta-analysis of randomised controlled trials.

Authors:  Sarah Stewart; Kevin Chih Kai Yang; Kate Atkins; Nicola Dalbeth; Philip C Robinson
Journal:  Arthritis Res Ther       Date:  2020-02-13       Impact factor: 5.156

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.